Researchers analyzed nationally representative data sets from 2017 and 2023 using Rome Foundation criteria, which are the global standard for diagnosing disorders of gut-brain interaction (DGBIs). These disorders include common but often misunderstood conditions like irritable bowel syndrome (IBS) and functional dyspepsia.

Sharp Increases in IBS and Functional Dyspepsia

The study found that disorders of gut-brain interaction became more common after the pandemic. In 2017, about 38% of people were affected, but by 2023, that number had grown to over 42%. Cases of irritable bowel syndrome (IBS) went up by 28%, increasing from 4.7% to 6%. Functional dyspepsia—a condition that causes ongoing discomfort in the upper stomach without a clear cause—rose even more sharply, jumping nearly 44% from 8.3% to 11.9%.

While these conditions are not new, the increase in their prevalence following the COVID-19 pandemic highlights a concerning trend. Researchers say the data provides the first direct, population-level evidence of how the pandemic has affected gut-brain health.

Long COVID Patients Most Affected

The study also found that individuals with long COVID—persistent symptoms lasting weeks or months after the initial infection—were significantly more likely to report gut-brain disorders. These patients also had higher levels of anxiety and depression and reported a lower overall quality of life.

This connection between long COVID and DGBIs supports previous hypotheses about the long-term effects of SARS-CoV-2 on the gut-brain axis. The virus is known to impact both the gastrointestinal system and the central nervous system, and researchers suggest these effects may persist long after the acute infection resolves.

Why the Gut-Brain Axis Matters

Disorders of gut-brain interaction happen when the signals between the digestive system and the brain don’t work properly, leading to ongoing gut symptoms without a clear physical cause. This can lead to chronic symptoms such as pain, bloating, irregular bowel movements, and nausea, without detectable physical abnormalities. These conditions are often linked with psychological factors like stress, anxiety, and depression.

The Rome Foundation criteria used in the study allow for precise diagnosis based on symptom patterns and have helped move these disorders out of the realm of “medically unexplained” and into evidence-based care.

A Call for Updated Care Models

The findings underline the need to adapt healthcare approaches in the post-pandemic era. Experts are calling for integrated treatment strategies that address both the physical and psychological aspects of gut-brain disorders.

“The data reinforces that long COVID is not just about fatigue or respiratory symptoms,” the researchers note. “It has lasting consequences for gastrointestinal and mental health.”

They also stress the importance of further research into how COVID-19 alters gut-brain signaling and why some individuals are more vulnerable to long-term effects.

[Source]

The post Why More People Are Struggling with Gut Issues After COVID appeared first on Medical Journal Daily.

Demographic Disparities in Long COVID

The survey, conducted by the US Agency for Healthcare Research and Quality and analyzed by statisticians Zhengyi Fang and Rebecca Ahrnsbrak, included responses from over 17,400 adults aged 18 and older. Of these, 8,275 individuals reported a prior infection with SARS-CoV-2, and 1,202 of them experienced long COVID symptoms such as fatigue, brain fog, and difficulty breathing.

The data revealed notable demographic differences:

• Gender: Females were more likely to report long COVID than males, with 8.6% of women compared to 5.1% of men.
• Age: Middle-aged adults showed higher rates of long COVID compared to younger and older adults, who tend to have better overall health and higher booster shot rates.
• Vaccination Status: Those who had received a booster shot exhibited lower rates of long COVID than those who had only two doses of a COVID-19 vaccine or were unvaccinated. This suggests that booster shots may enhance protection against long COVID by reducing the risk of severe COVID-19.

Risk Factors and Health Implications

Pre-existing health conditions such as chronic illnesses and obesity were identified as significant risk factors for long COVID. This aligns with previous studies highlighting high blood pressure, depression, diabetes, and chronic obstructive pulmonary disease (COPD) as contributing factors.

Global Perspectives on Long COVID

The prevalence of long COVID varies globally, influenced by differences in viral variants, vaccination rates, and study definitions. For instance:

• Scotland: A nationwide study reported that 6.5-10% of adults had long COVID 6-18 months post-infection.
• Australia: 5-10% of adults experienced persistent symptoms three months after testing positive.
• Netherlands: Approximately 12.7% of people had long COVID as of August 2022.

It is estimated that around 65 million people worldwide have developed long COVID, based on the assumption that 10% of the 651 million people who had COVID-19 by 2022 are affected. However, these figures are subject to debate due to potential underreporting and variations in data collection methods.

Ongoing Research and Healthcare Implications

Researchers continue to investigate the mechanisms behind long COVID to develop effective therapies. They also aim to answer fundamental questions about the prevalence and risk factors associated with long COVID. The findings emphasize the importance of recognizing and addressing the condition to inform healthcare responses and support affected individuals.

The comprehensive analysis of long COVID in the United States, published in JAMA, provides critical insights into the pandemic’s long-term effects and highlights the need for continued research and healthcare strategies to manage this chronic condition.

References:

1. Fang, Z., & Ahrnsbrak, R. (2023). Nationally Representative Household Survey Analysis. JAMA. Link
2. News Source: SciHB. Link

The post Almost 18 Million Adult Americans Have Had Long COVID: A Detailed Analysis appeared first on Medical Journal Daily.